Literature DB >> 10899278

The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction.

I Goldstein1.   

Abstract

The conditions of depression, erectile dysfunction (ED), and cardiovascular disease may seem at a superficial level as independent medical problems managed by 3 separate and unrelated healthcare disciplines. Various studies, however, have revealed significant associations between depression and cardiovascular disease, ED and cardiovascular disease, and depression and ED. The purpose of this research was to identify whether the 3 medical conditions share mutually reinforcing associations and predictors. Population-based epidemiologic studies were utilized where possible. Variables including age, heart disease, hypertension, sedentary behavior, related medications, cigarette smoking, and abnormal lipids have been found to be highly associated with depressive symptoms, cardiovascular disease, and ED. It was concluded that all 3 medical conditions share many of the same risk factors and etiologic associations and may be best modeled in a 3-way holistic, mutually reinforcing relation. Of particular relevance, patients with sexual dysfunction have a likely comorbidity of cardiovascular disease and depression, as well as the potential increased risk for cardiac morbidity and mortality.

Entities:  

Mesh:

Year:  2000        PMID: 10899278     DOI: 10.1016/s0002-9149(00)00892-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

Review 1.  Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression.

Authors:  L Zakaria; A G Anastasiadis; R Shabsigh
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Network position and sexual dysfunction: implications of partner betweenness for men.

Authors:  Benjamin Cornwell; Edward O Laumann
Journal:  AJS       Date:  2011-07

3.  Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage.

Authors:  Richard A Stein
Journal:  Rev Urol       Date:  2003

Review 4.  Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.

Authors:  Stephen L Archer; Ferrante S Gragasin; Linda Webster; Derek Bochinski; Evangelos D Michelakis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

5.  Blood Pressure, Sexual Activity, and Erectile Function in Hypertensive Men: Baseline Findings from the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Capri G Foy; Jill C Newman; Dan R Berlowitz; Laurie P Russell; Paul L Kimmel; Virginia G Wadley; Holly N Thomas; Alan J Lerner; William T Riley
Journal:  J Sex Med       Date:  2019-01-14       Impact factor: 3.802

Review 6.  Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials.

Authors:  Mariacristina Vecchio; Sankar D Navaneethan; David W Johnson; Giuseppe Lucisano; Giusi Graziano; Marialuisa Querques; Valeria Saglimbene; Marinella Ruospo; Carmen Bonifati; Emmanuele A Jannini; Giovanni F M Strippoli
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

Review 7.  Erectile dysfunction as a complication of heart failure.

Authors:  Afshan Baraghoush; Anita Phan; Robert D Willix; Ernst R Schwarz
Journal:  Curr Heart Fail Rep       Date:  2010-12

Review 8.  Sexual dysfunction in heart failure patients.

Authors:  Tiny Jaarsma; Bengt Fridlund; Jan Mårtensson
Journal:  Curr Heart Fail Rep       Date:  2014-09

Review 9.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.